Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Take Steps Now To Comply With IVDR Now Or Face The Consequences, Industry Told

Executive Summary

Notified bodies are taking the carrot and the stick approach as they urge manufacturers to make their IVDR applications now, especially for class D IVDs, or risk being non-complaint when the deadlines have passed.

You may also be interested in...



EU Lists Its First Reference Laboratories For High-Risk IVDs Falling Into Class D

There are 10 listings in the first  group of EU reference laboratory to be named. They will not formally assess IVDs for about a year and even then only evaluate products that are in a later batch to comply with the IVD Regulation.

EU Regulatory Roundup, November 2023: Notified Body Advances But Sector Still Demands System Rethink

There is currently a melting pot of ideas concerning the future of the EU’s medtech regulatory system due to its shortfalls. All the while progress is being made, especially in the area notified bodies.

European Commission Launches Data Collection Initiative To Avoid Medtech Product Shortfalls

There is a much-acknowledged urgency to ensure medtech products are certified as fast as possible, with fears persisting that delays will result in notified body bottlenecks and product shortages.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel